Chronic DiseaseNCT07718334
Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective
A study testing Mobile Application-Based Medication Reminder in people with Chronic Disease and Memory Impairment, run by Mansoura University at 2 sites in Egypt.
Trial summary
This study aims to evaluate the impact of using a mobile application-based medication reminder on medication adherence among patients diagnosed with chronic diseases and memory impairment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Disease, Memory Impairment
- What is being tested?
- Mobile Application-Based Medication Reminder
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 193 participants
- Where
- 2 sitesEgypt
- Study dates
- 10 May 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with one or more chronic diseases requiring regular long-term medication.
- Patients exhibiting mild-to-moderate memory impairment or cognitive decline as screened by the Mini-Mental State Examination (MMSE).
- Patients who personally own and are capable of operating a smartphone or have a primary caregiver willing to manage the mobile application.
- Patients aged 18 years and older.
- Patients who provide voluntary informed consent to participate in the study.
Who cannot join
- Patients with severe cognitive impairment or advanced dementia who cannot interact with mobile technology even with caregiver assistance.
- Patients with severe acute clinical complications or unstable psychiatric conditions.
- Patients participating in another concurrent clinical trial or study targeting medication adherence
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Mona Ahmed Gabr, PhD contact
Egypt2 sites, 2 recruiting
- Recruiting
Outpatient Clinics, Delta University for Science and Technology
Gamasa, Dakahlia Governorate
Asmaa Elwan Hassan, PhD, +201063776424, asmaaelwan@mans.edu.eg
Mona Ahmed Gabr, PhD
- Recruiting
Outpatient Clinics, Kafr El-Sheikh Hospital
Kafr ash Shaykh, Kafr el-Sheikh Governorate
Asmaa Elwan Hassan, PhD, +201063776424, asmaaelwan@mans.edu.eg
Mona Ahmed Gabr, PhD
About this study
Official title: Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective - A Quasi Experimental Study
This study aims to evaluate the impact of using a mobile application-based medication reminder on medication adherence among patients diagnosed with chronic diseases and memory impairment. Adherence to prescribed therapy is a significant challenge for this patient population, often leading to poor health outcomes and increased healthcare costs. From a nursing leadership perspective, innovative digital solutions can play a crucial role in supporting patient self-management. Using a quasi-experimental design, the study will investigate whether a customized mobile reminder system can effectively improve adherence rates and support patients in managing their therapeutic regimens.
Read the detailed description
Improving medication adherence in patients with chronic illnesses and cognitive decline is a key priority in healthcare management and nursing administration. This quasi-experimental study utilizes a pretest-posttest design to examine the effectiveness of a mobile application-based reminder system designed specifically for patients experiencing memory impairment.
Participants will be selected based on specific inclusion criteria, including being diagnosed with a chronic disease and exhibiting mild-to-moderate memory impairment. Baseline assessments (pretest) will be conducted to measure initial medication adherence levels, patient demographics, and health status. Following the baseline phase, the intervention will be introduced, where participants will utilize the mobile application to receive automated medication alerts and reminders over a specified period. Evaluation (posttest) will be performed post-intervention to analyze changes in adherence rates. The findings are expected to provide insights into how nursing leadership can leverage mobile health (mHealth) technology to design supportive care pathways, enhance patient independence, and reduce clinical complications associated with poor treatment adherence.
- Conditions
- Chronic Disease, Memory Impairment
- Being tested
- Mobile Application-Based Medication Reminder
- Keywords
- medication adherence, mobile application, medication reminder, nursing leadership, quasi-experimental study
- Medical subject headings
- Chronic Disease, Memory Disorders, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mobile Application-Based Medication ReminderDevice
The intervention consists of a mobile application specifically designed to support medication adherence. It features automated push notifications, customized reminder alerts matching prescribed medication schedules, and tracking logs. Participants will be instructed on how to install, configure, and use the application on their personal smartphones. The system is designed to provide immediate prompts to overcome memory-related adherence barriers.
| Study group | Role | What they receive |
|---|---|---|
| Mobile Application Group | Experimental | Participants in this single-group study will receive training on and utilize a customized mobile application-based medication reminder designed to support adherence to their therapeutic regimens. Receives: Device: Mobile Application-Based Medication Reminder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication Adherence (MMAS-8)
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). This self-reported tool evaluates patients' behaviors regarding taking their prescribed chronic medications. Total scores range from 0 to 8, where a score of 8 indicates high adherence, 6 to <8 indicates medium adherence, and <6 indicates low adherence.
Measured: Baseline (pre-intervention) and 3 months post-intervention
Secondary outcomes (4)
Objective Medication Adherence: Medication Possession Ratio (MPR)
Medication Possession Ratio (MPR) will be calculated using pharmacy refill records to determine the proportion of time the patient has access to their prescribed medication during the study period. Total scores will range from 0 to 1 (or 0% to 100%), with higher values indicating better adherence.
Measured: 3 months post-intervention
Objective Medication Adherence: Proportion of Days Covered (PDC)
Proportion of Days Covered (PDC) will be assessed using pharmacy refill records to measure the percentage of days the patient covered their prescribed medication dosage over the study duration. Total scores will range from 0 to 1 (or 0% to 100%), where higher values reflect superior medication adherence.
Measured: 3 months post-intervention
Cognitive Function Status (MMSE)
Cognitive impairment levels will be screened using the Mini-Mental State Examination (MMSE) to classify the severity of cognitive/memory impairment among participants.
Measured: Baseline
Perceived Nursing Care and Leadership Support
Evaluated using the Nursing Care and Leadership Support Assessment Tool to measure patient satisfaction and perception of the supportive role played by nursing leadership during the application-based program.
Measured: 3 months post-intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2026
- Study start10 May 2026
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic DiseaseStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 193 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Collaborators
- Al-Azhar University, Delta University for Science and Technology
- Responsible party
- Principal investigator, Asmaa Elwan Mohammed Hassan, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07718334
- Sponsor's protocol ID
- DFM-IRB 00012367- 26-04-001
- Status last verified
- Jul 2026
- First submitted
- 14 Jul 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared to ensure the confidentiality and privacy of the patients' medical records and personal information.
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective - A Quasi Experimental Study
- ClinicalTrials.gov ID
- NCT07718334
- Acronym / sponsor ID
- DFM-IRB 00012367- 26-04-001
- Conditions
- Chronic Disease, Memory Impairment
- Keywords
- medication adherence, mobile application, medication reminder, nursing leadership, quasi-experimental study
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 193 participants (estimated)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Collaborators
- Al-Azhar University, Delta University for Science and Technology
- Study start
- 10 May 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 21 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the impact of using a mobile application-based medication reminder on medication adherence among patients diagnosed with chronic diseases and memory impairment. Adherence to prescribed therapy is a significant challenge for this patient population, often leading to poor health outcomes and increased healthcare costs. From a nursing leadership perspective, innovative digital solutions can play a crucial role in supporting patient self-management. Using a quasi-experimental design, the study will investigate whether a customized mobile reminder system can effectively improve adherence rates and support patients in managing their therapeutic regimens.
Detailed description
Improving medication adherence in patients with chronic illnesses and cognitive decline is a key priority in healthcare management and nursing administration. This quasi-experimental study utilizes a pretest-posttest design to examine the effectiveness of a mobile application-based reminder system designed specifically for patients experiencing memory impairment.
Participants will be selected based on specific inclusion criteria, including being diagnosed with a chronic disease and exhibiting mild-to-moderate memory impairment. Baseline assessments (pretest) will be conducted to measure initial medication adherence levels, patient demographics, and health status. Following the baseline phase, the intervention will be introduced, where participants will utilize the mobile application to receive automated medication alerts and reminders over a specified period. Evaluation (posttest) will be performed post-intervention to analyze changes in adherence rates. The findings are expected to provide insights into how nursing leadership can leverage mobile health (mHealth) technology to design supportive care pathways, enhance patient independence, and reduce clinical complications associated with poor treatment adherence.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mobile Application Group | Experimental | Device: Mobile Application-Based Medication ReminderParticipants in this single-group study will receive training on and utilize a customized mobile application-based medication reminder designed to support adherence to their therapeutic regimens. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients diagnosed with one or more chronic diseases requiring regular long-term medication.
- Patients exhibiting mild-to-moderate memory impairment or cognitive decline as screened by the Mini-Mental State Examination (MMSE).
- Patients who personally own and are capable of operating a smartphone or have a primary caregiver willing to manage the mobile application.
- Patients aged 18 years and older.
- Patients who provide voluntary informed consent to participate in the study.
Key exclusion criteria (3 listed)
- Patients with severe cognitive impairment or advanced dementia who cannot interact with mobile technology even with caregiver assistance.
- Patients with severe acute clinical complications or unstable psychiatric conditions.
- Patients participating in another concurrent clinical trial or study targeting medication adherence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mobile Application-Based Medication ReminderThe intervention consists of a mobile application specifically designed to support medication adherence. It features automated push notifications, customized reminder alerts matching prescribed medication schedules, and tracking logs. Participants will be instructed on how to install, configure, and use the application on their personal smartphones. The system is designed to provide immediate prompts to overcome memory-related adherence barriers. | Device | Mobile Application Group |
Primary outcome
Medication Adherence (MMAS-8)
Time frame: Baseline (pre-intervention) and 3 months post-intervention
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). This self-reported tool evaluates patients' behaviors regarding taking their prescribed chronic medications. Total scores range from 0 to 8, where a score of 8 indicates high adherence, 6 to <8 indicates medium adherence, and <6 indicates low adherence.
4 secondary outcomes
Objective Medication Adherence: Medication Possession Ratio (MPR)
Time frame: 3 months post-intervention
Objective Medication Adherence: Proportion of Days Covered (PDC)
Time frame: 3 months post-intervention
Cognitive Function Status (MMSE)
Time frame: Baseline
Perceived Nursing Care and Leadership Support
Time frame: 3 months post-intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared to ensure the confidentiality and privacy of the patients' medical records and personal information.
Related trials for Chronic Disease
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mona Ahmed Gabr, PhD contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mobile Application-Based Medication Reminder in people with Chronic Disease and Memory Impairment, run by Mansoura University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Asmaa Elwan Hassan, PhD (+201063776424, asmaaelwan@mans.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication Adherence (MMAS-8) (time frame: Baseline (pre-intervention) and 3 months post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.